Deal title |
Principal |
Partner |
Total projected at signing (US$M) |
Start date |
April | ||||
ADC Therapeutics and Adagene to develop antibody drug conjugates using Safebody technology against a solid tumor target |
Adagene Suzhou Ltd. |
ADC Therapeutics Sarl |
Payment unspecified |
4/24/19 |
Undisclosed Switzerland company to commercialize AFT Pharmaceuticals' Maxigesic for treatment of pain in Switzerland |
AFT Pharmaceuticals Ltd. |
Undisclosed |
Payment unspecified |
4/12/19 |
Medochemie to commercialize AFT Pharmaceuticals' Maxigesic for treatment of pain in Cyprus |
AFT Pharmaceuticals Ltd. |
Medochemie Ltd. |
Payment unspecified |
4/12/19 |
Agilent to supply oligo microarrays to Somalogic for use in its Somascan assay |
Agilent Technologies Inc. |
Somalogic Inc. |
Payment unspecified |
4/30/19 |
Agomab and Argen-x to develop hepatocyte growth factor-mimetic agonistic monoclonal antibodies against fibrosis |
Agomab Therapeutics NV |
Argen-x NV |
Payment unspecified |
4/1/19 |
Vifor Pharma amended the agreement to sell Akebia's vadadustat to certain third-party dialysis organizations for use in the U.S. |
Akebia Therapeutics Inc. |
Vifor Pharma Ltd. |
$5.00 |
4/8/19 |
Allele and SCM to develop allogenic therapies using induced pluripotent stem cell technology for diabetes |
Allele Biotechnology and Pharmaceuticals Inc. |
SCM Lifescience Ltd. |
Payment unspecified |
4/15/19 |
Regeneron and Alnylam to discover, develop and commercialize RNAi therapeutics for ocular and central nervous system diseases, worldwide |
Alnylam Pharmaceuticals Inc. |
Regeneron Pharmaceuticals Inc. |
$1,435.00 |
4/8/19 |
Tetra Bio-Pharma and Altus to form joint venture to develop cannabinoid receptor targeted therapeutics for pain, oncology and ophthalmology |
Altus Formulation Inc. |
Tetra Bio-Pharma Inc. |
Payment unspecified |
4/29/19 |
CSC to promote and commercialize APR Applied Pharma's Diclofenac 50 mg powder oral solution for migraine in Russia |
APR Applied Pharma Research SA |
CSC Pharmaceuticals Handels GmbH |
Payment unspecified |
4/3/19 |
Xoma to acquire royalty rights to five of Aronora's hematology assets, including BAY-1213790, BAY-1831865, AB-023, AB-002 and AB-054 |
Aronora Inc. |
Xoma Corp. |
$434.00 |
4/7/19 |
Arteaus sells royalty interest in Emgality to Royalty Pharma |
Arteaus Therapeutics LLC |
Royalty Pharma |
$260.00 |
4/1/19 |
Eli Lilly and Avidity Biosciences to discover, develop and commercialize treatments for immunology and other selected indications worldwide |
Avidity Biosciences LLC |
Eli Lilly and Co. |
$440.00 |
4/22/19 |
Hope Medicine to develop and commercialize Bayer's BAY-1158061 directed against PRL receptor for male and female pattern hair loss and endometriosis worldwide |
Bayer AG |
Hope Medicine Inc. |
Payment unspecified |
4/7/19 |
Beigene to develop and commercialize Bioatla's BA-3071 as a monotherapy and in combination with tislelizumab for cancer worldwide |
Bioatla LLC |
Beigene Co. Ltd. |
$269.00 |
4/9/19 |
Biodextris to provide services related to development and manufacturing of clinical materials of I-Mab Biopharma's nasal adjuvants to treat neurological diseases |
Biodextris |
I-Mab Biopharma |
Payment unspecified |
4/5/19 |
Biorasi to provide clinical development services to Ivix's Libicore in the U.S. and European Union |
Biorasi LLC |
Ivix Ltd. |
Payment unspecified |
4/23/19 |
Biosyn to supply keyhole kimpet hemocyanin for the manufacture of Neovacs' IFN alpha kinoid |
Biosyn Arzneimittel GmbH |
Neovacs SA |
Payment unspecified |
4/1/19 |
Elpiscience Biopharma and Bio-Techne to develop anticancer therapeutics |
Bio-Techne Corp. |
Elpiscience Biopharmaceuticals Inc. |
Payment unspecified |
4/22/19 |
Casi to develop and commercialize Black Belt's TSK-011010 against multiple myeloma worldwide |
Black Belt Therapeutics Ltd. |
Casi Pharmaceuticals Inc. |
$7.95 |
4/16/19 |
Incyte and Briacell to evaluate the effects of Bria-IMT with INCMGA-0012 and epacadostat against advanced breast cancer |
Briacell Therapeutics Corp. |
Incyte Corp. |
Payment unspecified |
4/2/19 |
BMS to conduct a phase I/II clinical trial of Famewave's CM-24 in combination with nivolumab against non-squamous non-small cell lung cancer |
Bristol-Myers Squibb Co. |
Famewave Ltd. |
Payment unspecified |
4/12/19 |
Regeneron to use Calixar's membrane protein stabilization technology to develop antibodies against undisclosed targets |
Calixar SAS |
Regeneron Pharmaceuticals Inc. |
Payment unspecified |
4/29/19 |
Catalent to provide manufacture and supply services for phase II clinical trial of MGB Biopharma's MGB-BP-3 against Clostridium difficile-associated diarrhea |
Catalent Inc. |
MGB Biopharma Ltd. |
Payment unspecified |
4/25/19 |
Cellgen Diagnostics and GTC to provide services to accelerate development of companion tests for various oncology therapeutics |
Cellgen Diagnostics |
Genomic Testing Cooperative |
Payment unspecified |
4/3/19 |
Celltrion to develop, manufacture and supply four antibody drug conjugates against breast cancer, including HER2, CD20 and two additional targets using Iprogen's antibody delivery enhancing domain technology |
Celltrion Inc. |
Iprogen Biotech Inc. |
Payment unspecified |
4/8/19 |
Chr Hansen and Lonza to form a 50/50 joint venture as a contract development and manufacturing organization for live biotherapeutic products |
Chr Hansen Group |
Lonza AG |
Payment unspecified |
4/2/19 |
Cantabria to commercialize Crescita's Pliaglis for dermatology in Italy, Portugal, France and Spain |
Crescita Therapeutics Inc. |
Cantabria Labs Spain |
$2.84 |
4/25/19 |
Orpharma to market Cycle Pharmaceuticals' Nityr for type I tyrosinemia in Australia and New Zealand |
Cycle Pharmaceuticals Ltd. |
Orpharma Pty Ltd. |
Payment unspecified |
4/29/19 |
Dnanexus and Sutter Health to conduct research on clinico-genomic multiple sclerosis study |
Dnanexus Inc. |
Sutter Health |
Payment unspecified |
4/15/19 |
Editas and Bluerock to discover and develop new engineered cell medicines in neurology, cardiology, immunology and oncology |
Editas Medicine Inc. |
Bluerock Therapeutics |
Payment unspecified |
4/3/19 |
Adare to acquire rights for Egalet's Parvulet technology platform including related intellectual property to develop products worldwide |
Egalet Corp. |
Adare Pharmaceuticals Inc. |
Payment unspecified |
4/15/19 |
Sandoz to commercialize Eirgenix's trastuzumab biosimilar against HER2+ breast tumor worldwide, excluding China and Taiwan |
Eirgenix Inc. |
Sandoz International GmbH |
Payment unspecified |
4/30/19 |
Advanz Pharma to acquire Eisai's salagen and panretin against Kaposi's sarcoma and dry mouth |
Eisai Co. Ltd. |
Advanz Pharma Corp. |
$33.30 |
4/1/19 |
Eddingpharm to acquire Eli Lilly's antibiotic medicines, Ceclor and Vancocin, as well as a manufacturing facility in Suzhou, China |
Eli Lilly and Co. |
Eddingpharm Inc. |
$375.00 |
4/22/19 |
Nippon Kayaku to commercialize Eli Lilly's necitumumab for metastatic non-small-cell lung cancer in Japan |
Eli Lilly and Co. |
Nippon Kayaku Co. Ltd. |
Payment unspecified |
4/22/19 |
Takeda to acquire an option to use Emendobio's Omni technology for gene editing |
Emendobio Inc. |
Takeda Pharmaceutical Co. Ltd. |
Payment unspecified |
4/24/19 |
Aurora to use Enwave's radiant energy vacuum technology for cannabis production in the European Union excluding Portugal |
Enwave Corp. |
Aurora Cannabis Inc. |
Payment unspecified |
4/26/19 |
Thermo Fisher Scientific to use Epicypher's sample normalization and antibody profiling for chromatin immunoprecipitation technology to deliver antibodies for histone post-translational modifications |
Epicypher Inc. |
Thermo Fisher Scientific Inc. |
Payment unspecified |
4/24/19 |
Esteve Quimica to supply vadadustat API to Akebia |
Esteve Quimica SA |
Akebia Therapeutics Inc. |
Payment unspecified |
4/9/19 |
Sichuan Haisco to develop ExIthera's EP-7041 for knee injury in China |
ExIthera Pharmaceuticals Inc. |
Sichuan Haisco Pharmaceutical Co. Ltd. |
$6.00 |
4/2/19 |
Macrogen and Exosome Plus to develop exosome-based disease diagnosis and treatment solutions |
Exosome Plus |
Macrogen Inc. |
Payment unspecified |
4/19/19 |
Roche to spinout Nimble Therapeutics to accelerate chemical synthesis technology for the discovery and development of macrocyclic peptidomimetics |
F. Hoffmann-La Roche AG |
Nimble Therapeutics Inc. |
Payment unspecified |
4/30/19 |
Castle Creek Pharmaceuticals to develop and commercialize Fibrocell Science's FCX-007 gene therapy for the treatment of recessive dystrophic epidermolysis bullosa in the U.S. |
Fibrocell Science Inc. |
Castle Creek Pharmaceuticals LLC |
$135.00 |
4/15/19 |
Basilea to discover, develop and commercialize new antibiotic classes using Forge's Blacksmith metalloenzyme chemistry platform against infectious disease |
Forge Therapeutics Inc. |
Basilea Pharmaceutica International Ltd. |
$334.00 |
4/24/19 |
Brammer to manufacture and supply Freeline's FLT-180a for hemophilia B |
Freeline Therapeutics |
Brammer Biopharmaceuticals LLC |
Payment unspecified |
4/30/19 |
Clinigen to commercialize GC Pharma's Hunterase for the treatment of Hunter syndrome in Japan |
GC Pharma |
Clinigen Group plc |
Payment unspecified |
4/3/19 |
Fulcrum Therapeutics to develop and commercialize GSK's losmapimod for facioscapulohumeral muscular dystrophy worldwide |
Glaxosmithkline plc |
Fulcrum Therapeutics Inc. |
Payment unspecified |
4/23/19 |
Kaken Pharmaceutical to develop and commercialize Hitgen's small molecule drugs against an undisclosed target using DNA-encoded library design, synthesis and screening platform |
Hitgen Ltd. |
Kaken Pharmaceutical Co. Ltd. |
Payment unspecified |
4/10/19 |
Johnson & Johnson and Holobiome to collaborate on development of bacterial consortia to treat digestive disorders |
Holobiome Inc. |
Johnson & Johnson |
Payment unspecified |
4/2/19 |
Thyas to use ID Pharma's Cytotune-Ips tecnology to manufacture differentiated induced pluripotent stem cells against cancer in Japan |
ID Pharma Co. Ltd. |
Thyas Co. Ltd. |
Payment unspecified |
4/12/19 |
Janssen Pharmaceutica to use Iktos' artificial intelligence technology for application in small molecule drug discovery projects |
Iktos SAS |
Janssen Pharmaceutica NV |
Payment unspecified |
4/29/19 |
Roche to evaluate I-Mab Biopharma's TJD-5 in combination with atezolizumab against cancer |
I-Mab Biopharma |
Roche Holding AG |
Payment unspecified |
4/10/19 |
Spectrum to acquire Immungene's FIT technology platform and to develop two early stage therapies against B-cell lymphoma |
Immungene Inc. |
Spectrum Pharmaceuticals Inc. |
$159.00 |
4/15/19 |
Immunomedics to promote Janssen's erdafitinib for metastatic urothelial cancer in the U.S. |
Immunomedics Inc. |
Janssen Biotech Inc. |
Payment unspecified |
4/8/19 |
Everest Medicines to develop and commercialize Immunomedics' sacituzumab govitecan against solid tumors in certain Asian countries |
Immunomedics Inc. |
Everest Medicines |
$835.00 |
4/29/19 |
Aqilion and Immunscape to evaluate and develop drug development project |
Immunscape AB |
Aqilion AB |
Payment unspecified |
4/25/19 |
Evotec and Indivumed to discover therapeutics for the treatment of colorectal cancer |
Indivumed GmbH |
Evotec SE |
Payment unspecified |
4/11/19 |
Variant to develop and commercialize Inflamacore's IC-100 for inflammatory renal and autoimmune diseases worldwide |
Inflamacore LLC |
Variant Pharmaceuticals Inc. |
Payment unspecified |
4/22/19 |
Gilead and Insitro to discover and develop therapies using insitro human platform for nonalcoholic steatohepatitis |
Insitro |
Gilead Sciences Inc. |
$1,050.00 |
4/16/19 |
International Isotopes to provide contract manufacturing and supply services to Progenics for Azedra and other iodine products |
International Isotopes Inc. |
Progenics Pharmaceuticals Inc. |
Payment unspecified |
4/9/19 |
Ips Academia Japan to grant Heartseed worldwide rights to use induced pluripotent stem cell-derived cardiomyocytes products for regenerative therapy |
Ips Academia Japan Inc. |
Heartseed Inc. |
Payment unspecified |
4/15/19 |
Ironwood Pharmaceuticals to spin out Cyclerion Therapeutics for the discovery, development and commercialization of soluble guanylate cyclase modulators for serious and orphan diseases |
Ironwood Pharmaceuticals Inc. |
Cyclerion Therapeutics Inc. |
Payment unspecified |
4/1/19 |
Ohara and J-Pharma to jointly develop JPH-203 against solid tumors including advanced biliary cancer in Asia, including Japan and China, as well as Africa |
J-Pharma Co. Ltd. |
Ohara Pharmaceutical Co. Ltd. |
Payment unspecified |
4/25/19 |
Bayer and Khloris Biosciences to develop induced pluripotent stem cells as anti-cancer vaccines |
Khloris Biosciences Inc. |
Bayer AG |
Payment unspecified |
4/2/19 |
Lakepharma to provide integrated discovery and development services to Twist Bioscience to discover antibody against protein drug targets |
Lakepharma Inc. |
Twist Bioscience Corp. |
Payment unspecified |
4/4/19 |
Nobelpharma to develop LTT Bio-Pharma's LT-5001 for neurological diseases |
LTT Bio-Pharma Co. Ltd. |
Nobelpharma Co. Ltd. |
Payment unspecified |
4/9/19 |
Lupin and Natco to jointly commercialize bosentan tablets for pulmonary arterial hypertension |
Lupin Ltd. |
Natco Pharma Ltd. |
Payment unspecified |
4/29/19 |
Cytovant to develop and commercialize Medigene's T cell immunotherapies, including NY-ESO-1, DC vaccine and T-cell receptors for two additional targets against cancer in East Asia |
Medigene AG |
Cytovant Sciences HK Ltd. |
$1,010.00 |
4/4/19 |
Aresus Pharma acquires worldwide excluding U.S. rights for Medigene's Veregen |
Medigene AG |
Aresus Pharma GmbH |
$8.80 |
4/8/19 |
Bausch Health to develop and commercialize MTPC's MT-1303 for autoimmune diseases worldwide, except Japan and other Asian countries |
Mitsubishi Tanabe Pharma Corp. |
Bausch Health Companies Inc. |
Payment unspecified |
4/25/19 |
Salix to develop and commercialize MTPC's MT-1303 against ulcerative colitis worldwide, excluding Japan and other countries in Asia |
Mitsubishi Tanabe Pharma Corp. |
Salix Pharmaceuticals Ltd. |
Payment unspecified |
4/26/19 |
Virpax to use Nanomerics' molecular envelope technology to develop intranasal formulation of NES-100 for chronic pain worldwide |
Nanomerics Ltd. |
Virpax Pharmaceuticals Inc. |
Payment unspecified |
4/16/19 |
Novartis spins off eye care division, Alcon |
Novartis AG |
Alcon Inc. |
Payment unspecified |
4/9/19 |
Novo Nordisk to initiate a proof-of-concept study by combining semaglutide with Gilead's cilofexor and firsocostat in nonalcoholic steatohepatitis patients |
Novo Nordisk A/S |
Gilead Sciences Inc. |
Payment unspecified |
4/12/19 |
Nuformix and Ebers Tech to develop and commercialize cannabinoid therapeutics |
Nuformix Ltd. |
Ebers Tech Inc. |
$66.40 |
4/9/19 |
Mati Therapeutics to settle litigation with Ocular Therapeutix related to Dextenza for eye disease |
Ocular Therapeutix Inc. |
Mati Therapeutics Inc. |
Payment unspecified |
4/30/19 |
Chugai to develop, manufacture and market Oncolys' Telomelysin against cancer in Japan and Taiwan |
Oncolys Biopharma Inc. |
Chugai Pharmaceutical Co. Ltd. |
$465.74 |
4/8/19 |
Tetra Bio-Pharma to evaluate Ovensa's Triozan delivery platform for targeted delivery of cannabinoids to brain tumor cells |
Ovensa Inc. |
Tetra Bio-Pharma Inc. |
Payment unspecified |
4/11/19 |
Luye Pharma to develop and commercialize Pharmamar's Zepsyre for small-cell lung cancer in China |
Pharmamar SA |
Luye Pharma Group Ltd. |
$5.00 |
4/26/19 |
Immunoforge to develop and commercialize Phasebio's PB-1023 for all diseases, including sarcopenia-related diseases worldwide |
Phasebio Pharmaceuticals Inc. |
Immunoforge Co. Ltd. |
Payment unspecified |
4/9/19 |
Wacker Biotech and Phasebio to manufacture and commercialize PB-2452 against bleeding |
Phasebio Pharmaceuticals Inc. |
Wacker Biotech GmbH |
Payment unspecified |
4/23/19 |
Encore to market and distribute Promius' Sernivo spray 0.05%, Promiseb topical cream and Trianex 0.05% in the U.S. |
Promius Pharma LLC |
Encore Dermatology Inc. |
Payment unspecified |
4/2/19 |
Cipla to co-develop and commercialize Pulmatrix's pulmazole for allergic bronchopulmonary aspergillosis worldwide |
Pulmatrix Inc. |
Cipla Ltd. |
$22.00 |
4/1/19 |
Puretech and Boehringer to develop immuno-oncology products using Puretech's lymphatic targeting technology for immune modulation |
Puretech Health plc |
Boehringer Ingelheim International GmbH |
$226.00 |
4/17/19 |
Teva Pharmaceutical to develop Recro's Verapamil SR capsules for essential hypertension in the U.S. |
Recro Gainesville LLC |
Teva Pharmaceutical Industries Ltd. |
Unknown |
4/16/19 |
Fosun Pharma to develop, manufacture and commercialize Reneuron's CTX and human retinal progenitor cell therapy programs against disability caused by stroke and retinitis pigmentosa in China |
Reneuron Group plc |
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. |
$112.70 |
4/9/19 |
Biosense to develop and commercialize Rexahn's RX-3117 against pancreatic cancer and other cancers in Republic of Singapore, China, Hong Kong, Macau and Taiwan, with an option to develop the product for additional indications |
Rexahn Pharmaceuticals Inc. |
Biosense Global LLC |
$229.00 |
4/16/19 |
Oncology Venture to obtain an option to acquire commercial rights of R-Pharm's Ixempra for breast cancer in the European Union |
R-Pharm |
Oncology Venture A/S |
Payment unspecified |
4/4/19 |
Samsung Biologics to provide manufacturing services for Cytodyn's biodrugs including Leronlimab for human immunodeficiency virus infection |
Samsung Biologics Co. Ltd. |
Cytodyn Inc. |
$277.00 |
4/1/19 |
Ascentage to evaluate APG-1387 in combination with Shanghai Junshi Biosciences' toripalimab against solid and hematological tumors |
Shanghai Junshi Biosciences Co. Ltd. |
Ascentage Pharma Group Corp. Ltd. |
Payment unspecified |
4/8/19 |
Sandoz to sell Shionogi's Rizmoic for opioid-induced constipation in Germany, the U.K. and the Netherlands |
Shionogi and Co. Ltd. |
Sandoz International GmbH |
Payment unspecified |
4/11/19 |
Biodelivery Sciences International to commercialize Shionogi's Symproic in the U.S. and Puerto Rico for the treatment of opioid-induced constipation |
Shionogi Inc. |
Biodelivery Sciences International Inc. |
$30.00 |
4/4/19 |
Shanghai Miracogen to use Synaffix's Glycoconnect and Hydraspace technologies for the development and commercialization of antibody drug conjugate product against cancer |
Synaffix BV |
Shanghai Miracogen Biotechnology Co. Ltd. |
$125.00 |
4/10/19 |
Tessa and Merck to evaluate combination of TT-12 and Keytruda against metastatic cervical cancer |
Tessa Therapeutics Pte Ltd. |
Merck & Co. Inc. |
Payment unspecified |
4/15/19 |
Novasep to gain rights to use DNA Flap technology from Theravectys for manufacturing GMP grade lentiviral vectors worldwide |
Theravectys |
Novasep |
Payment unspecified |
4/16/19 |
Pandion to use Twist Bioscience's antibody optimization technology to develop bispecific antibodies to treat autoimmune and inflammatory disease |
Twist Bioscience Corp. |
Pandion Therapeutics Inc. |
Payment unspecified |
4/11/19 |
SK Biopharmaceuticals and Twoxar to discover and develop treatments for non-small-cell lung cancer |
Twoxar Inc. |
SK Biopharmaceuticals |
Payment unspecified |
4/17/19 |
ANI Pharmaceuticals to distribute an undisclosed U.S. based manufacturer's injectable product |
Undisclosed |
ANI Pharmaceuticals Inc. |
$2.00 |
4/15/19 |
Dr. Reddy's Laboratories to acquire 42 approved, non-marketed abbreviated new drug applications in the U.S. from an undisclosed company |
Undisclosed |
Dr. Reddy's Laboratories Ltd. |
Payment unspecified |
4/13/19 |
Urogen Pharma and Janssen to conduct an early stage feasibility evaluation in an undisclosed therapeutic area |
Urogen Pharma Ltd. |
Janssen Research and Development LLC |
Payment unspecified |
4/23/19 |
U.S. Bioservice to distribute Biocodex's Diacomit for the treatment of seizures associated with Dravet syndrome |
U.S. Bioservices |
Biocodex USA |
Payment unspecified |
4/24/19 |
Velabs and Chiome to discover modulatory and functional antibodies for one of Chiome's G-protein-coupled receptor target genes worldwide |
Velabs Therapeutics GmbH |
Chiome Bioscience Inc. |
Payment unspecified |
4/24/19 |
Virpax and Kannaba Technologies to research, develop and commercialize cannabinoid-based products using combined delivery technolgoy against pain |
Virpax Pharmaceuticals |
Kannaba Technologies Inc. |
Payment unspecified |
4/8/19 |
Wuxi to provide development and manufacturing services for NBE-Therapeutics' NBE-002 for cancer |
Wuxi Biologics |
NBE-Therapeutics Ltd. |
Payment unspecified |
4/8/19 |
Xcella and Teva to identify rare antibodies against an undisclosed target using xploration single cell screening platform |
Xcella Biosciences Inc. |
Teva Pharmaceuticals Australia Pty Ltd. |
Payment unspecified |
4/9/19 |
Astellas Pharma to access Xencor's Xmab bispecific Fc domain technology to generate, develop and commercialize bispecific antibodies for the treatment of cancer worldwide |
Xencor Inc. |
Astellas Pharma Inc. |
Payment unspecified |
4/2/19 |
Ohara to acquire patent rights related to Zenyaku's ZSTK-474 worldwide |
Zenyaku Kogyo Co. Ltd. |
Ohara Pharmaceutical Co. Ltd. |
Payment unspecified |
4/19/19 |
May | ||||
Abbvie to settle patent litigation with BI for intellectual property related to Humira in the U.S. |
Abbvie Inc. |
Boehringer Ingelheim International GmbH |
Payment unspecified |
5/14/19 |
Abcellera to develop a platform capable of creating field-ready medical countermeasures within 60 days of a pandemic viral outbreak using Ichor's Trigrid electroporation-mediated nucleic acid administration platform |
Abcellera Biologics Inc. |
Ichor Medical Systems Inc. |
Payment unspecified |
5/10/19 |
Accredo to supply Titan Pharmaceuticals' Probuphine for opioid use disorder in the U.S. |
Accredo Health Group Inc. |
Titan Pharmaceuticals Inc. |
Payment unspecified |
5/13/19 |
Forty Seven and Acerta Pharma to evaluate immune oncology triple combination drug in diffuse large B cell lymphoma |
Acerta Pharma BV |
Forty Seven Inc. |
Payment unspecified |
5/10/19 |
Nordic Bioscience to evaluate AKL Research and Development's Appa for osteoarthritis |
AKL Research and Development Ltd. |
Nordic Bioscience A/S |
Payment unspecified |
5/2/19 |
Adaptimmune and Alpine Immune Sciences to develop next-generation human induced pluripotent stem cell-derived allogeneic specific peptide enhanced affinity receptor T-cell products for cancer, with an option for worldwide rights |
Alpine Immune Sciences Inc. |
Adaptimmune Therapeutics plc |
$290 |
5/14/19 |
Altasciences to provide clinical research services to Wuxi Apptec to support wind technology for drug development |
Altasciences Clinical Research |
Wuxi Apptec (Suzhou) Co. Ltd. |
Payment unspecified |
5/16/19 |
ACTC and Eisai to evaluate BAN-2401 for Alzheimer's disease |
Alzheimer's Clinical Trials Consortium |
Eisai Co. Ltd. |
Payment unspecified |
5/10/19 |
Boehringer to evaluate a phase Ib (KISIMA-01) study of Amal Therapeutics's ATP-128 in combination with BI-754091 against stage IV colorectal cancer |
Amal Therapeutics SA |
Boehringer Ingelheim International GmbH |
Payment unspecified |
5/2/19 |
Lupin to market Aptissen's products in Canada |
Aptissen SA |
Lupin Ltd. |
Payment unspecified |
5/9/19 |
Intelgenx and Aquestive to co-develop tadalafil oral films for erectile dysfunction worldwide |
Aquestive Therapeutics Inc. |
Intelgenx Technologies Corp. |
Payment unspecified |
5/8/19 |
Astrazeneca and Sensei to conduct two phase II combination studies of SNS-301 with Imfinzi in head and neck cancer patients |
Astrazeneca plc |
Sensei Biotherapeutics Inc. |
Payment unspecified |
5/7/19 |
Aurora Cannabis and UFC to advance clinical research on hemp-derived Cannabidiol products for pain, inflammation and injury |
Aurora Cannabis Inc. |
Ultimate Fighting Championship |
Payment unspecified |
5/21/19 |
Be The Match Biotherapies to provide end-to-end support services for clinical development of Poseida's BCMA and PSMA chimeric antigen receptor T cell programs |
Be The Match Biotherapies |
Poseida Therapeutics Inc. |
Payment unspecified |
5/14/19 |
Verve Therapeutics to access Beam Therapeutics' base editing, gene editing and delivery technologies for human therapeutic applications against certain cardiovascular targets |
Beam Therapeutics |
Verve Therapeutics Inc. |
Payment unspecified |
5/7/19 |
Astrazeneca and Benevolentai to use artificial intelligence and machine learning to develop treatments against chronic kidney disease and idiopathic pulmonary fibrosis |
Benevolentai Ltd. |
Astrazeneca plc |
Payment unspecified |
5/1/19 |
Novartis to use Codexis' Codeevolver protein engineering platform to develop performance enzymes |
Codexis Inc. |
Novartis AG |
Payment unspecified |
5/15/19 |
Westmed Medical and Columbia Care to study the therapeutic effectiveness and safety of medical cannabis as a pain reliever in rheumatologic patients with inflammatory arthritis |
Columbia Care LLC |
Westmed Medical Group |
Payment unspecified |
5/21/19 |
Corerx to manufacture and supply Aimmune's AR-101 against peanut allergy |
Corerx Inc. |
Aimmune Therapeutics Inc. |
Payment unspecified |
5/14/19 |
Takeda to develop Curadev's CRD-5500 for cancer |
Curadev Pharma Pvt. Ltd. |
Takeda Pharmaceutical Co. Ltd. |
Payment unspecified |
5/8/19 |
Meroven to market and distribute Cure Pharmaceutical's Spee-D in the U.S. |
Cure Pharmaceutical Holding Corp. |
Meroven LLC |
Payment unspecified |
5/3/19 |
Dyadic and Alphazyme to develop medicines and diagnostic tools using gene expression platform |
Dyadic International Inc. |
Alphazyme LLC |
Payment unspecified |
5/6/19 |
Dyadic and Serum Institute to develop and manufacture twelve antibodies and vaccine using C1 gene expression platform |
Dyadic International Inc. |
Serum Institute of India Ltd. |
Payment unspecified |
5/7/19 |
Eurofins to provide genetic biomarker testing to support Adial's AD-04 phase III clinical trial for alcohol use disorder |
Eurofins Scientific |
Adial Pharmaceuticals LLC |
Payment unspecified |
5/7/19 |
ASC Therapeutics to use Expression Therapeutics' critical technologies for hemophilia A gene therapy |
Expression Therapeutics LLC |
ASC Therapeutics |
Payment unspecified |
5/16/19 |
Valirx to acquire worldwide granted patents and intellectual property assets from FIT Biotech worldwide |
FIT Biotech Oyj plc |
Valirx plc |
$0.01 |
5/2/19 |
FSD Pharma and Solarvest Bioenergy to develop algae-based pharmaceutical grade cannabinoids |
FSD Pharma Inc. |
Solarvest Bioenergy Inc. |
$1.00 |
5/7/19 |
Genocea to evaluate Iovance's tumor-infiltrating lymphocyte products using its neoantigen identification platform, Atlas platform |
Genocea Biosciences Inc. |
Iovance Biotherapeutics Inc. |
Payment unspecified |
5/15/19 |
Gilead Sciences and Goldfinch Bio to discover, develop and commercialize new therapies for diabetic kidney disease and orphan kidney disease |
Goldfinch Bio Inc. |
Gilead Sciences Inc. |
$2,059.00 |
5/8/19 |
Harbour Biomed and Chia Tai Tianqing to discover, develop and commercialize biologics for multiple therapeutic targets in oncology and immunology in multiple territories |
Harbour Biomed Ltd. |
Chia Tai Tianqing Pharmaceutical Group Co. Ltd. |
Payment unspecified |
5/5/19 |
Medavate to acquire Neocart assets from Histogenics |
Histogenics Corp. |
Medavate Corp. |
$6.5 |
5/8/19 |
Exelixis and Iconic Therapeutics to develop an antibody drug conjugate program for cancer and an option to license ICON-2 |
Iconic Therapeutics Inc. |
Exelixis Inc. |
$7.50 |
5/16/19 |
HLS Therapeutics to commercialize Indivior's Perseris for schizophrenia in Canada |
Indivior plc |
HLS Therapeutics Inc. |
$5.00 |
5/9/19 |
Innovation and undisclosed pharmaceutical company to sign non-binding term sheet to develop and commercialize Brilacidin for ulcerative proctitis/ulcerative proctosigmoiditis worldwide |
Innovation Pharmaceuticals Inc. |
Undisclosed |
Payment unspecified |
5/16/19 |
Merck to explore Intec Pharma's accordion pill drug delivery platform for an undisclosed program |
Intec Pharma Ltd. |
Merck & Co. Inc. |
Payment unspecified |
5/16/19 |
Myungmoon Pharm to commercialize Kerastem's hair growth therapy in South Korea, China and ASEAN member states |
Kerastem Technologies |
Myungmoon Pharm Co. Ltd. |
$140.00 |
5/14/19 |
Kymera and Vertex to discover and develop small molecule protein degraders using Pegasus drug discovery platform for multiple targets |
Kymera Therapeutics LLC |
Vertex Pharmaceuticals Inc. |
$1070 |
5/15/19 |
Motif Bio to assess delivery of LMS-611 with Lamellar Biomedical's lamellasome technology for cystic fibrosis |
Lamellar Biomedical Ltd. |
Motif Bio plc |
Payment unspecified |
5/1/19 |
Lonza to manufacture and supply Chiasma's Mycapssa for acromegaly |
Lonza Group AG |
Chiasma Inc. |
Payment unspecified |
5/14/19 |
Biontech acquires Mabvax Therapeutics' MVT-5873 and other preclinical antibody assets |
Mabvax Therapeutics Holdings Inc. |
Biontech SE |
Payment unspecified |
5/8/19 |
Australasian Medical to market and distribute Mannkind's Afrezza inhalation powder for diabetes in Australia |
Mannkind Corp. |
Australasian Medical and Scientific Ltd. |
Payment unspecified |
5/16/19 |
Eisai to commercialize Medac's methotrexate injection for rheumatoid arthritis in Japan |
Medac GmbH |
Eisai Co. Ltd. |
Payment unspecified |
5/10/19 |
Vericel to commercialize Mediwound's Nexobrid in North America for burn care |
Mediwound Ltd. |
Vericel Corp. |
$150.00 |
5/6/19 |
Grow Biotech to distribute MGC Pharma's Cannepil for epilepsy and Cognicann for dementia and Alzheimer's disease in U.K. |
MGC Pharma |
Grow Biotech plc |
Payment unspecified |
5/6/19 |
Molteni to distribute Shionogi's Rizmoic for opioid-induced constipation in Italy and Poland |
Molteni Farmaceutici |
Shionogi & Co. Ltd. |
Payment unspecified |
5/22/19 |
Kyorin to enter into a memorandum of understanding to co-market MSD Japan's MK-7264 for chronic cough in Japan |
MSD Japan |
Kyorin Holdings Inc. |
Payment unspecified |
5/13/19 |
Pneuma Respiratory to develop Leads Biolabs' monoclonal antibodies and fusion protein molecules for pulmonary delivery against oncologic or immune-mediated lung diseases |
Nanjing Leads Biolabs Co. Ltd. |
Pneuma Respiratory Inc. |
Payment unspecified |
5/15/19 |
Cstone Pharmaceuticals to develop and commercialize Numab Therapeutics' ND-021 for cancer in greater China, including mainland China, Hong Kong, Macau and Taiwan, South Korea and Singapore |
Numab Therapeutics AG |
Cstone Pharmaceuticals Co. Ltd. |
Payment unspecified |
5/1/19 |
Hanx to develop and commercialize Onconova's Rigosertib for the treatment of higher-risk myelodysplastic syndromes in greater China |
Onconova Therapeutics Inc. |
Hanx Biopharmaceuticals Inc. |
$51.50 |
5/13/19 |
Primo Trading to distribute and commercialize Optibiotix's Slimbiome for weight loss in the Thailand |
Optibiotix Health plc |
Primo Trading Co. Ltd. |
Payment unspecified |
5/14/19 |
Gene Techno Science and Orthorebirth to develop therapeutics for cleft lip or cleft palate |
Orthorebirth Co. Ltd. |
Gene Techno Science Co. Ltd. |
Payment unspecified |
5/10/19 |
Otonomy to co-promote Glenmark's Otiprio for acute otitis externa in the U.S. |
Otonomy Inc. |
Glenmark Therapeutics Inc. |
Payment unspecified |
5/2/19 |
Oxford Genetics and CGT Catapult to develop scalable lentiviral manufacturing processes |
Oxford Genetics Ltd. |
Cell and Gene Therapy Catapult |
Payment unspecified |
5/13/19 |
Genentech to develop and commercialize Parvus' Navacim therapeutics against inflammatory bowel disease, autoimmune liver diseases and celiac disease worldwide |
Parvus Therapeutics Inc. |
Genentech Inc. |
$800.00 |
5/16/19 |
Patheon Biologics to produce Cantargia's CAN-04 for pancreatic and non-small-cell lung cancers |
Patheon Biologics BV |
Cantargia AB |
Payment unspecified |
5/13/19 |
FLX Bio to use Personalis' Immunoid Next to evaluate FLX-475 or in combination with pembrolizumab against cancer |
Personalis Inc. |
FLX Bio Inc. |
Payment unspecified |
5/20/19 |
Biocure Pharm and Pharos Vaccine to develop anti-CD19 chimeric antigen receptor T-cell therapy products for leukemia and lymphoma worldwide, except China |
Pharos Vaccine Inc. |
Biocure Pharm Corp. |
Payment unspecified |
5/17/19 |
Panaxia and Plantext to co-develop medical cannabis products for inflammatory bowel disease, Crohn's disease and colitis |
Plantext Ltd. |
Panaxia Pharmaceutical Industries Ltd. |
Payment unspecified |
5/1/19 |
Presage Biosciences to evaluate Celgene's early stage assets in phase 0 trials and patients' responses to microdoses of multiple cancer drugs using Presage's Civo platform |
Presage Biosciences Inc. |
Celgene Corp. |
Payment unspecified |
5/2/19 |
Vaccitech to use Probiogen's AGE1.CR duck retina cell line technology to produce viral vectored vaccines, including VTP-100 |
Probiogen AG |
Vaccitech Ltd. |
Payment unspecified |
5/15/19 |
Rotop to develop and commercialize Progenics' imaging agent, 1404, against prostate cancer in Europe |
Progenics Pharmaceuticals Inc. |
Rotop Pharmaka GmbH |
Payment unspecified |
5/14/19 |
Prolynx and Daiichi Sankyo to use drug delivery linker technology to extend the intravitreal half-life of Daiichi's candidates |
Prolynx LLC |
Daiichi Sankyo Co. Ltd. |
Payment unspecified |
5/3/19 |
Qiagen and Inovio to co-develop liquid biopsy-based precision medicine test for VGX-3100 to treat precancerous cervical lesions |
Qiagen NV |
Inovio Pharmaceuticals Inc. |
Payment unspecified |
5/16/19 |
Reform Biologics to conduct feasibility studies to enhance the formulation of Bayer's two clinical-stage programs |
Reform Biologics LLC |
Bayer AG |
Payment unspecified |
5/14/19 |
Cincor to develop and commercialize Roche's CIN-107 for resistant hypertension and primary aldosteronism worldwide |
Roche Holding AG |
Cincor Pharma Inc. |
Payment unspecified |
5/14/19 |
Skyhawk and Takeda to discover and develop RNA splicing modifiers for neurological diseases using Skystar technology worldwide |
Skyhawk Therapeutics Inc. |
Takeda Pharmaceutical Co. Ltd. |
Payment unspecified |
5/6/19 |
Arcus to use Strata's drug development platform and biomarkers for evaluation of AB-122 against cancers |
Strata Oncology |
Arcus Biosciences Inc. |
$2.50 |
5/2/19 |
Novartis to acquire Takeda's Xiidra for dry eye disease worldwide |
Takeda Pharmaceutical Co. Ltd. |
Novartis AG |
$5,300.00 |
5/8/19 |
Ethicon to acquire Takeda's Tachosil for hemostasis |
Takeda Pharmaceutical Co. Ltd. |
Ethicon Inc. |
$400.00 |
5/8/19 |
Takeda Pharmaceuticals to spin out Phathom Pharmaceuticals to develop and commercialize therapeutics, including vonoprazan for acid-related gastrointestinal disorders in the U.S., Europe and Canada |
Takeda Pharmaceutical Co. Ltd. |
Phathom Pharmaceuticals Inc. |
Payment unspecified |
5/15/19 |
Bicycle Therapeutics and DDF to develop therapeutics using bicyclic peptide technology for neurodegenerative diseases, including dementia |
The Dementia Discovery Fund |
Bicycle Therapeutics Ltd. |
Payment unspecified |
5/7/19 |
Transgene and Astrazeneca to develop oncolytic vaccinia virus candidates using Invir.IO |
Transgene SA |
Astrazeneca plc |
$13.00 |
5/2/19 |
Valirx to sign letter of intent with Alpha Blue Ocean to form a genetic therapeutic and diagnostic based joint venture |
Valirx plc |
Alpha Blue Ocean Advisors Ltd. |
Payment unspecified |
5/2/19 |
Vectura to enter settlement for resolving litigation of U.S. sales of GSK's Breo Ellipta, Anoro Ellipta and Incruse Ellipta |
Vectura Group plc |
Glaxosmithkline plc |
$89.70 |
5/3/19 |
Verve to use Verily's nanoparticle screening platform for new gene editing delivery vehicles for cardiovascular diseases |
Verily Life Sciences LLC |
Verve Therapeutics Inc. |
Payment unspecified |
5/7/19 |
Viiv Healthcare to evaluate Matinas Biopharma's lipid nanocrystal formulation of antiviral drug candidates |
Viiv Healthcare Ltd. |
Matinas Biopharma Holdings Inc. |
Payment unspecified |
5/15/19 |
Virogin Biotech and China National Biotec to form joint venture to commercialize oncolytic virotherapies |
Virogin Biotech Canada Ltd. |
China National Biotec Group |
Payment unspecified |
5/8/19 |
Ginkgo Bioworks acquires Warp Drive Bio's genome mining platform to discover and develop antibiotics for drug-resistant bacterial infections |
Warp Drive Bio |
Ginkgo Bioworks |
Payment unspecified |
5/15/19 |
Hoth to enter into a non-binding term sheet to co-develop Zylo's anandamide loaded Z-pods for cutaneous lupus erythematosus |
Zylo Therapeutics LLC |
Hoth Therapeutics Inc. |
Payment unspecified |
5/14/19 |
Iconic to use Zymeworks' Zymelink antibody drug conjugate (ADC) platform to develop ICON-2 Tissue Factor ADC against cancer worldwide |
Zymeworks Inc. |
Iconic Therapeutics Inc. |
Payment unspecified |
5/14/19 |
GSK expanded the 2016 agreement, valued at $908M, to gain further access to Zymeworks' Azymetric technology to develop bispecific and multifunctional therapeutics, paying $1.1B in total |
Zymeworks Inc. |
Glaxosmithkline plc |
$192.00 |
5/17/19 |
|
Notes This chart includes only biopharmaceutical deals between companies. Deals with universities and nonprofit entities, as well as mergers and acquisitions, will be highlighted in separate charts. For more information about individual companies and/or products, see Cortellis. | ||||